Fibronostics to Present LIVERFASt Data at DDW 2026
Fibronostics is pleased to share that Dr. Mona Munteanu, Chief Scientific Officer at Fibronostics, will be presenting new data on […]
Fibronostics is pleased to share that Dr. Mona Munteanu, Chief Scientific Officer at Fibronostics, will be presenting new data on […]
Fibronostics is pleased to announce that new data on LIVERFASt™, its non-invasive blood-based diagnostic test for liver disease, will be
Non-invasive tests (NITs) have transformed how we identify and manage metabolic liver disease. Yet as MASLD and MASH prevalence continues
Aim: This study evaluates the diagnostic performance of the novel blood-based device, LIVERFASt to detect fibrosis stages in patients with metabolic
Fibronostics is excited to announce our participation in the MASH-TAG 2026 Conference, held from January 8-10, 2026, in beautiful Deer
At Fibronostics, our mission is built on a foundation of precision and trust. We are proud to announce that we
Turmeric has long held a place in traditional wellness, but curcumin, its active compound, is now capturing clinical interest. With
If you’re managing type 2 diabetes, it’s easy to focus on blood sugar numbers and forget one of your most
The poster presents a retrospective study on the use of non-invasive tests (NITs) to initiate and monitor Resmetirom (RT) therapy
When we think of metabolic health, the liver and pancreas often operate behind the scenes, regulating fat metabolism, insulin balance,